Journal
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
Volume 70, Issue 4, Pages 299-308Publisher
WILEY
DOI: 10.1111/aji.12130
Keywords
Antiphospholipid antibodies; endometrial angiogenesis; TIFL
Categories
Funding
- MIUR GRANT (COFIN PRIN) [2006061255]
- Ricerca Corrente IRCCS Istituto Auxologico Italiano
- ISI (Istituto Scientifico Internazionale), Istituto Paolo VI, Universita Cattolica del Sacro Cuore, Rome, Italy
Ask authors/readers for more resources
Problem Aim of our study was to investigate whether TIFI, a syntetic peptide able to compete with anti-phospholipid antibodies (aPL) in the binding to endothelium, may restore aPL-inhibited endometrial angiogenesis. Methods The protective role of TIFI was evaluated on: i) aPL-inhibited of human endometrial endothelial cells (HEEC) angiogenesis in vitro; ii) aPL-inhibited vascular endothelial growth factor (VEGF) and metalloproteases (MMPs) expression; iii) aPL-inhibited Nuclear Factor-kappa B (NF-kappa B) and Extracellular signal-Regulated Kinase (ERK) activation and (iv) angiogenesis in vivo. Results TIFI restores in a dose-dependent manner: i) aPL-mediated inhibition of HEEC angiogenesis in vitro and in vivo (P < 0.05), ii) VEGF (P < 0.001) and MMP-2 (P < 0.05) expression and iii) NF-kappa B DNA binding and ERK-1/2 activation (P < 0.05) inhibited by aPL. Conclusion Our results show for the first time the protective effects of TIFI, as represented by its ability to interfere with aPL mediated anti-angiogenic activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available